Your Health, We Care
brigatinib is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
from FDA，2022.02
The treatment of locally advanced or metastatic non-small cell lung cancer (NSCL···【more】
Release date：2026-01-05Recommended：0
